AstraZeneca will end U.S. commercial sales of Andexxa Dec. 22, citing safety concerns raised in postmarketing data and a recent trial, according to a Dec. 18 FDA news release. Andexxa, a recombinant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback